尊龙凯时人生就是搏·(中国区)官方网站

VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TDI01 SUSPENSION (“ROCK2 INHIBITOR”) INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CDE

VOLUNTARY ANNOUNCEMENT - THE LATEST PROGRESS OF INNOVATION-DRIVEN DEVELOPMENT OF THE GROUP

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 10 JUNE 2025

VOLUNTARY ANNOUNCEMENT

AMENDED AND RESTATED ARTICLES OF ASSOCIATION

VOLUNTARY ANNOUNCEMENT - TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" OBTAINING APPROVAL FOR PHASE III REGISTRATIONAL CLINICAL STUDY FROM CDE

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART WITH OR WITHOUT ANLOTINIB AS MAINTENANCE TREATMENT FOR NON-SMALL CELL LUNG CANCER WITHOUT PROGRESSION FOLLOWING CHEMORADIOTHERAPY PRESENTED AT 2025 ASCO ANNUAL MEETING

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER PRESENTED AT 2025 ASCO ANNUAL MEETING